Please login to the form below

Not currently logged in
Email:
Password:

romosozumab

This page shows the latest romosozumab news and features for those working in and with pharma, biotech and healthcare.

CHMP says OK to UCB/Amgen’s Evenity for osteoporosis after appeal

CHMP says OK to UCB/Amgen’s Evenity for osteoporosis after appeal

The Committee for Medicinal Products for Human Use (CHMP) issued a  negative opinion on first-in-class antibody Evenity (romosozumab) in June, but re-examined the drug after an appeal by

Latest news

More from news
Approximately 6 fully matching, plus 15 partially matching documents found.

Latest Intelligence

  • Investing in the future of R&D Investing in the future of R&D

    One of UCB's brightest prospects is its osteoporosis candidate romosozumab. In January phase II trial results were published that showed significant increases in low bone mineral density at both spine

  • VIDEO interview: Neil Weir, UCB VIDEO interview: Neil Weir, UCB

    Providing an example, he explains UCB's use of genetics in its development of romosozumab, currently in phase III investigation in partnership with Amgen for use in the treatment of ... UCB's work on romosozumab with Amgen is also an example of the

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics